ストックスクリーナーアプリを入手
1.19
0.83%
-0.01
アフターアワーズ：
1.21
0.02
+1.68%
前日終値:
$1.20
開ける：
$1.23
24時間の取引高:
852.59K
Relative Volume:
1.34
時価総額：
$108.09M
収益：
-
当期純損益:
$-93.61M
株価収益率:
-0.3469
EPS:
-3.43
ネットキャッシュフロー:
$-71.16M
1週間 パフォーマンス:
-9.16%
1か月 パフォーマンス:
-26.09%
6か月 パフォーマンス:
-13.14%
1年 パフォーマンス:
+5.31%
1日の値動き範囲:
$1.19
$1.255
1週間の範囲:
$1.15
$1.33
52週間の値動き範囲:
$0.9451
$2.11
Immunic Inc Stock (IMUX) Company Profile
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-10-21 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2021-04-15 | 開始されました | Aegis Capital | Buy |
| 2021-03-24 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-02 | 開始されました | SVB Leerink | Outperform |
| 2020-08-26 | 開始されました | Piper Sandler | Overweight |
| 2020-08-07 | 再開されました | ROTH Capital | Buy |
| 2020-07-20 | 開始されました | BMO Capital Markets | Outperform |
| 2020-06-05 | 開始されました | Wedbush | Outperform |
| 2020-05-11 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-25 | 開始されました | ROTH Capital | Buy |
| 2019-07-11 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Immunic Inc (IMUX) 最新ニュース
Immunic's Jessica Breu talks BIO-Europe & MS research advancements - Proactive Investors USA
Vanguard Group's Strategic Acquisition of Immunic Inc Shares - GuruFocus.com
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - Quantisnow
Immunic (IMUX) Set to Announce Quarterly Earnings on Thursday - MarketBeat
Immunic to Participate in Industry, Scientific and Investor Conferences in November - StockTitan
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.20 - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.5% in October - MarketBeat
Reviewing Immunic (NASDAQ:IMUX) & Acasti Pharma (NASDAQ:ACST) - Defense World
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - Simply Wall St
Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials - Proactive Investors Australia
Immunic late-stage program for lead asset to proceed as planned - MSN
Data monitoring committee OKs continuation of phase 3 trial for vidofludimus calcium - Healio
Interim analysis allows Immunic to stick with phase III MS studies - BioWorld Online
Immunic stock slips after trial update (IMUX:NASDAQ) - Seeking Alpha
Immunic Phase 3 MS study advances following positive recommendation from independent committee - Proactive financial news
Immunic Shares Up 12% on Positive MS Drug Analysis - MarketWatch
Immunic's phase 3 ENSURE trials for MS drug proceed as planned - Investing.com
Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - Marketscreener.com
EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosisboerse.de - boerse.de
Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq
FY2024 EPS Estimates for Immunic Lowered by Analyst - MarketBeat
Research Analysts Offer Predictions for Immunic Q4 Earnings - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat
We Think Immunic (NASDAQ:IMUX) Needs To Drive Business Growth Carefully - Yahoo Canada Finance
Focus on long-term protection - European Biotechnology News
Stock Surge: Immunic Inc (IMUX) Closes at 1.40, Marking a 0.00 Increase/Decrease - The Dwinnex
Investing in Immunic Inc (IMUX) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Marshall Wace LLP Has $44,000 Stock Holdings in Immunic, Inc. (NASDAQ:IMUX) - Defense World
Renaissance Technologies LLC Has $323,000 Stake in Immunic, Inc. (NASDAQ:IMUX) - MarketBeat
Immunic Inc (IMUX) Q2 2024 Earnings Call Highlights: Promising Clinical Data and Financial ... - Yahoo Finance UK
Future of oral small molecule drugs – addressing potential in multiple sclerosis - European Pharmaceutical Review
Immunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from Analysts - MarketBeat
Immunic CMO on key ECTRIMS highlights and MS research - Proactive Investors USA
Get in on Immunic Inc’s (IMUX) buy-in window today! - SETE News
IMUX’s 2023 Market Saga: Unraveling the Story of Gains and Losses - The InvestChronicle
Market Momentum Report: Immunic Inc (IMUX)’s Negative Close at 1.60 - The Dwinnex
Analysts review Immunome Inc’s rating - Knox Daily
Immunome (NASDAQ:IMNM) Shares Down 5.6% After Insider Selling - MarketBeat
IMAX (NYSE:IMAX) Stock Price Down 4.9% - Defense World
Ratio Review: Analyzing Imunon Inc (IMNN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
IMAX Co. (NYSE:IMAX) Shares Sold by Rhumbline Advisers - Defense World
What is the investor’s view on Immunic Inc (IMUX)? - US Post News
Immuneering Corp Inc. (IMRX) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle
Hancock Whitney Corp Sells 2,958 Shares of Polaris Inc. (NYSE:PII) - Defense World
You might want to take a look at Inuvo Inc (INUV) now - SETE News
Imunon Inc (IMNN) may enjoy gains as insiders got busy in the recent days - Knox Daily
Applied Fundamental Research LLC Decreases Stock Holdings in UFP Technologies, Inc. (NASDAQ:UFPT) - MarketBeat
UniQure rises on orphan drug status for genetic disorder gene therapy - XM
uniQure Gains FDA Orphan Drug Status for Fabry Disease Therapy - TipRanks
UFP Industries, Inc. (NASDAQ:UFPI) Holdings Decreased by Seven Eight Capital LP - Defense World
Unichem Laboratories Set To Discuss US Business Consolidation At Upcoming Board Meeting - NDTV Profit
Immunic Inc (IMUX) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):